Celmatix, a New York-based biotechnology firm, will launch a randomized prospective clinical trial this month to test Polaris, a web-based clinical decision support system that the company developed to help physicians predict women's potential of getting pregnant with or without the use of fertility treatments such as in vitro fertilization and make decisions about appropriate courses of action.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.